RECURRENT FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE

Clinical trials for RECURRENT FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE explained in plain language.

Never miss a new study

Get alerted when new RECURRENT FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE trials appear

Sign up with your email to follow new studies for RECURRENT FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

New Immune-Targeting drug tested for Tough-to-Treat blood cancers

Disease control Ongoing

This is an early-stage study to find the safest dose of an experimental immunotherapy drug called MEDI-570. It is for adults with specific types of advanced T-cell lymphoma that have come back or stopped responding to previous treatments. The main goals are to check for side effe…

Matched conditions: RECURRENT FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Apr 01, 2026 14:42 UTC

RECURRENT FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE

Get alerted when new RECURRENT FOLLICULAR HELPER T-CELL LYMPHOMA, ANGIOIMMUNOBLASTIC-TYPE trials appear

New Immune-Targeting drug tested for Tough-to-Treat blood cancers